Pfizer Completes Acquisition of Clinical-Stage Biotech
Pfizer has successfully completed its acquisition of Therachon, a privately held clinical-stage biotechnology company.
Pfizer has successfully completed its acquisition of Therachon, a privately held clinical-stage biotechnology company, it was announced in a July 1, 2019 press release.
The acquisition was completed for US$340 million with an additional US$470 million in supplementary payments. The additional payments are dependent on key milestones being achieved in the development and commercialization of an investigational medicine for the treatment of achondroplasia, TA-46.
“Therachon becoming part of Pfizer is representative of our Rare Disease team’s 30-year commitment to develop innovative medicines that address significant unmet medical needs of people with rare diseases,” said Seng Cheng, senior vice-president and chief scientific officer of Pfizer’s Rare Disease Research Unit, in a press release. “With our leading scientific and development capabilities, we believe we can effectively advance the development of TA-46, which has the potential to be a first-in-class therapy for the treatment of achondroplasia.”
Source: Pfizer
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
VERAXA and Voyager to Create Combined Business for Advancing Pipeline of Next-Gen Cancer Therapies
April 23rd 2025The proposed business combination would create a publicly traded, clinical-stage biopharmaceutical company that will focus on developing a pipeline of next-generation cancer therapies.
